Lumos Diagnostics Holdings Ltd（澳大利亚证券交易所代码：LDX）宣布与Phase Scientific达成一项关键独家分销协议，在美国市场推广其产品Febridx。这份为期六年的合约价值可能高达3.17亿美元，其中包括200万美元的即时付款。此举标志着双方在医疗诊断领域的深度合作，为Febridx在美国的推广奠定坚实基础。
Lumos Diagnostics Holdings Ltd（澳大利亚证券交易所代码：LDX）宣布与Phase Scientific达成一项关键独家分销协议，在美国市场推广其产品Febridx。这份为期六年的合约价值可能高达3.17亿美元，其中包括200万美元的即时付款。此举标志着双方在医疗诊断领域的深度合作，为Febridx在美国的推广奠定坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.